CN105457157B - 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 - Google Patents
电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 Download PDFInfo
- Publication number
- CN105457157B CN105457157B CN201510716613.XA CN201510716613A CN105457157B CN 105457157 B CN105457157 B CN 105457157B CN 201510716613 A CN201510716613 A CN 201510716613A CN 105457157 B CN105457157 B CN 105457157B
- Authority
- CN
- China
- Prior art keywords
- skin
- electroporation
- energy
- pulse
- electrodes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004520 electroporation Methods 0.000 title claims abstract description 417
- 238000000034 method Methods 0.000 title claims abstract description 70
- 210000004962 mammalian cell Anatomy 0.000 title abstract description 9
- 210000001519 tissue Anatomy 0.000 claims abstract description 175
- 206010033675 panniculitis Diseases 0.000 claims abstract description 9
- 210000004304 subcutaneous tissue Anatomy 0.000 claims abstract description 9
- 210000003205 muscle Anatomy 0.000 claims description 47
- 230000004044 response Effects 0.000 claims description 29
- 230000005684 electric field Effects 0.000 claims description 26
- 230000007935 neutral effect Effects 0.000 claims description 22
- 238000004891 communication Methods 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 9
- 230000000149 penetrating effect Effects 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 4
- -1 nickel metal hydride Chemical class 0.000 claims description 4
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical group [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- OJIJEKBXJYRIBZ-UHFFFAOYSA-N cadmium nickel Chemical compound [Ni].[Cd] OJIJEKBXJYRIBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910001416 lithium ion Inorganic materials 0.000 claims description 3
- 229910052987 metal hydride Inorganic materials 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 40
- 210000003491 skin Anatomy 0.000 description 325
- 239000013612 plasmid Substances 0.000 description 121
- 239000007924 injection Substances 0.000 description 56
- 238000002347 injection Methods 0.000 description 56
- 230000014509 gene expression Effects 0.000 description 55
- 241001465754 Metazoa Species 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 52
- 238000002474 experimental method Methods 0.000 description 46
- 238000002649 immunization Methods 0.000 description 44
- 230000003053 immunization Effects 0.000 description 43
- 238000007918 intramuscular administration Methods 0.000 description 33
- 238000009472 formulation Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 23
- 230000008713 feedback mechanism Effects 0.000 description 23
- 239000003814 drug Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 230000008569 process Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 241000282887 Suidae Species 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 12
- 108010041986 DNA Vaccines Proteins 0.000 description 11
- 229940021995 DNA vaccine Drugs 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 238000002847 impedance measurement Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 7
- 241000282553 Macaca Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 102100022831 Somatoliberin Human genes 0.000 description 6
- 101710142969 Somatoliberin Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 238000010304 firing Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229920002643 polyglutamic acid Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000012811 non-conductive material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000013492 plasmid preparation Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 238000011238 DNA vaccination Methods 0.000 description 3
- 238000011510 Elispot assay Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 108091005971 Wild-type GFP Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000012073 inactive phase Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 238000012768 mass vaccination Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 210000000438 stratum basale Anatomy 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 210000000439 stratum lucidum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- ZCJJIQHVZCFSGZ-UHFFFAOYSA-N 2,8-bis(diphenylphosphoryl)dibenzothiophene Chemical compound C=1C=CC=CC=1P(C=1C=C2C3=CC(=CC=C3SC2=CC=1)P(=O)(C=1C=CC=CC=1)C=1C=CC=CC=1)(=O)C1=CC=CC=C1 ZCJJIQHVZCFSGZ-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100285408 Danio rerio eng2a gene Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000689006 Syntrophorhabdaceae Species 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000009464 antigen specific memory response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000005428 wave function Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0476—Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Electrotherapy Devices (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85214906P | 2006-10-17 | 2006-10-17 | |
| US60/852149 | 2006-10-17 | ||
| US97898207P | 2007-10-10 | 2007-10-10 | |
| US60/978982 | 2007-10-10 | ||
| CNA2007800466527A CN101563132A (zh) | 2006-10-17 | 2007-10-17 | 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800466527A Division CN101563132A (zh) | 2006-10-17 | 2007-10-17 | 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105457157A CN105457157A (zh) | 2016-04-06 |
| CN105457157B true CN105457157B (zh) | 2020-04-14 |
Family
ID=38935920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510716613.XA Active CN105457157B (zh) | 2006-10-17 | 2007-10-17 | 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9452285B2 (enExample) |
| EP (4) | EP2066399B1 (enExample) |
| JP (1) | JP5439183B2 (enExample) |
| KR (1) | KR101421760B1 (enExample) |
| CN (1) | CN105457157B (enExample) |
| AU (1) | AU2007313203B2 (enExample) |
| CA (1) | CA2666501C (enExample) |
| DK (2) | DK2066399T3 (enExample) |
| ES (2) | ES2993941T3 (enExample) |
| FI (1) | FI3524316T3 (enExample) |
| HU (2) | HUE042044T2 (enExample) |
| LT (1) | LT3524316T (enExample) |
| PL (2) | PL3524316T3 (enExample) |
| PT (2) | PT3524316T (enExample) |
| SG (1) | SG175627A1 (enExample) |
| WO (1) | WO2008048632A1 (enExample) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101529448B1 (ko) * | 2006-03-03 | 2015-06-18 | 온코섹 메디컬 인코포레이티드 | 외과적 절제술 이후에 조직내 남아 있는 미세 잔류 종양을 치료하는 장치 |
| US7687267B2 (en) * | 2006-09-30 | 2010-03-30 | Rational Biotechnology Inc. | High-throughput cell transfection device and methods of using thereof |
| CN101877965B (zh) | 2007-11-12 | 2014-08-20 | 宾夕法尼亚大学托管会 | 针对流感病毒的多种亚型的疫苗 |
| JP2011504173A (ja) * | 2007-11-14 | 2011-02-03 | ブイジーエックス ファーマシューティカルズ，リミティド ライアビリティー カンパニー | 電気穿孔により送達されるｄｎａワクチンにより誘導される抗体の産生 |
| CN107083391A (zh) * | 2008-04-04 | 2017-08-22 | 宾夕法尼亚大学托管会 | 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法 |
| AU2009231598B2 (en) | 2008-04-04 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
| ITCO20080016A1 (it) * | 2008-04-22 | 2009-10-23 | Giuseppe Caccia | Manipolo per elettroporazione di prodotti farmacologici e/o naturali e/o estetici su strati cutanei a spessore contenuto |
| US8921536B2 (en) | 2008-10-29 | 2014-12-30 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
| KR101609233B1 (ko) | 2008-10-29 | 2016-04-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개량된 ｈｃｖ 백신 및 이를 이용하는 방법 |
| US8961994B2 (en) | 2008-11-17 | 2015-02-24 | Vgx Pharmaceuticals, Llc | DNA constructs eliciting immune response against flavivirus and effective adjuvants |
| US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
| ES2902988T3 (es) | 2009-04-16 | 2022-03-30 | Inovio Pharmaceuticals Inc | Electrodo y procedimiento de electropermeabilización sin contacto |
| US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| CN102656260A (zh) * | 2009-10-19 | 2012-09-05 | 瑞生生物技术有限公司 | 用于诱导自调节细胞电穿孔的方法、装置和设备 |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| AU2011223768B2 (en) * | 2010-03-01 | 2014-10-30 | Inovio Pharmaceuticals, Inc. | Multiple tissue layer electroporation applicator and device |
| US9700368B2 (en) | 2010-10-13 | 2017-07-11 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
| CA2825950C (en) | 2011-01-28 | 2019-06-18 | The General Hospital Corporation | Method and apparatus for skin resurfacing |
| CN103635152B (zh) | 2011-01-28 | 2017-02-15 | 通用医疗公司 | 用于不连续皮肤磨削的方法和装置 |
| EP2667805B1 (en) | 2011-01-28 | 2023-04-05 | The General Hospital Corporation | Apparatus and method for tissue biopsy |
| JP6099573B2 (ja) | 2011-01-31 | 2017-03-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法 |
| KR101363000B1 (ko) * | 2011-03-03 | 2014-02-24 | 라종주 | 피부 미용방법, 미용기 및 미용 시스템 |
| ITTO20110374A1 (it) * | 2011-04-29 | 2012-10-30 | Igea S P A | Metodo di controllo di un dispositivo di elettro-porazione |
| HK1197039A1 (zh) | 2011-06-15 | 2015-01-02 | Chrontech Pharma Ab | 注射针和装置 |
| KR102171142B1 (ko) * | 2011-06-28 | 2020-10-28 | 이노비오 파마수티컬즈, 인크. | 최소 침습 피부 전기천공 장치 |
| AU2015203882C1 (en) * | 2011-06-28 | 2017-09-21 | Inovio Pharmaceuticals, Inc. | A minimally invasive dermal electroporation device |
| ES2693162T3 (es) | 2011-07-21 | 2018-12-07 | The General Hospital Corporation | Instrumental para dañar y eliminar grasa |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| CN102680526B (zh) * | 2012-05-16 | 2014-07-02 | 清华大学 | 单细胞阵列微芯片及其制造、电测量和电穿孔方法 |
| KR101979746B1 (ko) * | 2012-09-13 | 2019-05-17 | (주)아모레퍼시픽 | 전기 천공 장치 |
| US20140171957A1 (en) * | 2012-12-19 | 2014-06-19 | Alcon Research, Ltd. | Control of Automated Intraocular Lens Injectors |
| CN107398013A (zh) * | 2012-12-24 | 2017-11-28 | 电子运动医疗有限公司 | 用于唤起胃肠器官中连续的肌肉收缩的装置 |
| BR112015019440A8 (pt) | 2013-02-20 | 2019-11-12 | Cytrellis Biosystems Inc | curativo regulável, kit, uso e método para fortalecimento da pele |
| KR102349218B1 (ko) | 2013-08-09 | 2022-01-10 | 사이트렐리스 바이오시스템즈, 인크. | 비-열적 조직 절제를 사용한 피부 치료를 위한 방법 및 기구 |
| WO2015095675A1 (en) | 2013-12-19 | 2015-06-25 | Cytrellis Biosystems, Inc. | Methods and devices for manipulating subdermal fat |
| US11260137B2 (en) * | 2014-04-06 | 2022-03-01 | Emily Chen Tang | Electroporation apparatuses and their method of use |
| US12114911B2 (en) * | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| AU2015346141B2 (en) | 2014-11-14 | 2021-07-22 | Cytrellis Biosystems, Inc. | Devices and methods for ablation of the skin |
| WO2016161201A2 (en) * | 2015-03-31 | 2016-10-06 | Oncosec Medical Incorporated | Systems and methods for improved tissue-sensing based electroporation |
| WO2016161113A1 (en) * | 2015-03-31 | 2016-10-06 | University Of South Florida | System and method for electroporation controlled by electrical impedance measurements |
| US11027071B2 (en) * | 2015-12-28 | 2021-06-08 | Inovio Pharmaceuticals, Inc. | Intradermal jet injection electroporation device |
| ITUB20159819A1 (it) * | 2015-12-31 | 2017-07-01 | Biopulse S R L | Elettroporatore teranostico ad onda bifasica per la diagnosi delle aree patologiche ed il trasferimento terapeutico di molecole e relativo procedimento |
| WO2017136758A1 (en) | 2016-02-05 | 2017-08-10 | Inovio Pharmaceuticals, Inc. | Cancer vaccines and methods of treatment using the same |
| ES3021258T3 (en) | 2016-03-29 | 2025-05-26 | Cytrellis Biosystems Inc | Devices for cosmetic skin resurfacing |
| US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| EP3515323A4 (en) | 2016-09-21 | 2020-06-10 | Cytrellis Biosystems, Inc. | COSMETIC RESTRUCTURING DEVICES AND METHODS |
| MX2019004499A (es) | 2016-10-17 | 2019-11-18 | Janssen Pharmaceuticals Inc Star | Sistemas de replicón de virus recombinante y usos de estos. |
| JP7158820B2 (ja) * | 2016-10-26 | 2022-10-24 | ロレアル | エレクトロポレーションデバイスおよびエレクトロポレーションデバイスを制御するための方法 |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| AU2017372731B2 (en) | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| KR20180123312A (ko) * | 2017-05-08 | 2018-11-16 | (주)오스힐 | 미세전류 조절 수단을 구비한 스킨 부스터 |
| JP6518971B2 (ja) * | 2017-05-12 | 2019-05-29 | 株式会社ベックス | エレクトロポレーター用電源 |
| CN107126628A (zh) * | 2017-06-14 | 2017-09-05 | 重庆百国智科技发展有限公司 | 一种人体电位差细胞补水及生物电信号修复的装置及其方法 |
| DE102017116305A1 (de) * | 2017-07-19 | 2019-01-24 | Cinogy Gmbh | Plasma-Behandlungsgerät |
| SE541651C2 (en) | 2017-07-28 | 2019-11-19 | Scandinavian Chemotech Ab | An electrode device and a needle electrode for use in delivery of electrical pulses to a desired tissue of a mammal |
| JP7485600B2 (ja) | 2017-12-13 | 2024-05-16 | イノビオ ファーマシューティカルズ，インコーポレイティド | Ｂｏｒｉｓを標的とするがんワクチンおよびその使用 |
| WO2019118760A1 (en) | 2017-12-13 | 2019-06-20 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting mesothelin and uses thereof |
| RU2750689C1 (ru) | 2017-12-13 | 2021-07-01 | Иновио Фармасьютикалз, Инк. | Противораковые вакцины, направленные на muc16, и их применение |
| SG11202005710YA (en) | 2017-12-19 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| KR20200101416A (ko) | 2017-12-19 | 2020-08-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv) 백신 및 그 용도 |
| CA3089024A1 (en) | 2018-01-19 | 2019-07-25 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| KR102132370B1 (ko) * | 2018-03-13 | 2020-08-05 | 주식회사 지씨에스 | 피부관리장치, 피부관리장치의 구동방법 및 컴퓨터 판독가능 기록매체 |
| JP7594298B2 (ja) * | 2018-08-01 | 2024-12-04 | オハイオ・ステイト・イノベーション・ファウンデーション | 皮膚をインスリン産生組織にリプログラミングするための組成物および方法 |
| BR112021006614A2 (pt) | 2018-10-08 | 2021-07-20 | Janssen Pharmaceuticals, Inc. | replicons com base em alfavírus para administração de bioterápicos |
| EP3673846A1 (en) * | 2018-12-27 | 2020-07-01 | Bogdan Ionescu | Device for an electrophysiology procedure |
| US11071860B2 (en) * | 2019-02-06 | 2021-07-27 | Oncosec Medical Incorporated | Systems and methods for detecting fault conditions in electroporation therapy |
| WO2020255022A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors |
| CA3141003A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
| WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| WO2020255017A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CA3141323A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Recombinant interleukin 12 construct and uses thereof |
| JP2022536850A (ja) | 2019-06-18 | 2022-08-19 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| CA3140690A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| WO2020255042A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative |
| WO2020255016A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| WO2020255019A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative |
| US20220305107A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020255013A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives |
| US20220305116A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences lreland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives |
| WO2020255035A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives |
| US20220324916A1 (en) | 2019-06-18 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Hepatitis B Virus (HBV) Vaccines and Uses Thereof |
| CA3140588A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor |
| US20220241402A1 (en) | 2019-06-18 | 2022-08-04 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
| MA56533A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 |
| US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| MA56534A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) |
| EP3986563A1 (en) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
| US20220290183A1 (en) * | 2019-08-30 | 2022-09-15 | Virginia Tech Intellectual Properties, Inc. | Method for intracellular delivery of compounds using cell force and shape with electric fields |
| BR112022018409A2 (pt) * | 2020-03-20 | 2022-12-06 | Inovio Pharmaceuticals Inc | Dispositivos de eletroporação assistida a vácuo e sistemas e métodos relacionados |
| CN111581642A (zh) * | 2020-05-03 | 2020-08-25 | 付贵龙 | 一种互联网安全防护系统 |
| WO2021252354A1 (en) | 2020-06-12 | 2021-12-16 | University Of Rochester | ENCODING AND EXPRESSION OF ACE-tRNAs |
| US12496442B2 (en) | 2020-06-30 | 2025-12-16 | Industrial Technology Research Institute | Microneedle electroporation device |
| IL299571A (en) | 2020-07-08 | 2023-02-01 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| US12006507B2 (en) | 2020-07-22 | 2024-06-11 | Nantcell, Inc. | Electroporation with active compensation |
| US12076071B2 (en) | 2020-08-14 | 2024-09-03 | Kardium Inc. | Systems and methods for treating tissue with pulsed field ablation |
| US20220071692A1 (en) * | 2020-09-08 | 2022-03-10 | Biosense Webster (Israel) Ltd. | Impedance based irreversible-electroporation (ire) |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| US20240316090A1 (en) | 2020-12-28 | 2024-09-26 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| CA3243439A1 (en) | 2022-02-07 | 2023-08-10 | University Of Rochester | SEQUENCES OPTIMIZED FOR ENHANCED DNA EXPRESSION AND/OR NONSENSE MUTATION DELETION |
| JP2025507714A (ja) * | 2022-02-25 | 2025-03-21 | イノビオ ファーマシューティカルズ，インコーポレイティド | 手持ち式エレクトロポレーション装置、及び関連システム、並びに方法 |
| EP4518957A1 (en) * | 2022-05-05 | 2025-03-12 | Renbio, Inc. | Device related to therapeutic dna delivery |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| EP4634373A1 (en) | 2022-12-16 | 2025-10-22 | University of Rochester | Repairment of barrier dysfunction in esophagus |
| WO2025101685A1 (en) | 2023-11-09 | 2025-05-15 | University Of Rochester | Suppression of nonsense mutations using anticodon engineered (ace)-trnas |
| CN120436779B (zh) * | 2025-07-01 | 2025-09-30 | 北京航空航天大学青岛研究院 | 十二指肠粘膜表面置换与电转染一体化设备及基于参数反馈运行的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| CN1345610A (zh) * | 2000-09-30 | 2002-04-24 | 杭州泰士生物科技有限公司 | 一种活体组织电穿孔用的波形及波形发生器 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2798459B2 (ja) * | 1988-01-21 | 1998-09-17 | マサチユセツツ・インスチチユート・オブ・テクノロジー | エレクトロポレーションを利用した診断装置及び分子の組織内移動装置 |
| US5545130A (en) | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| CA2337652C (en) | 1998-07-13 | 2013-03-26 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| WO2000002620A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
| US6972013B1 (en) * | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US6192270B1 (en) | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
| US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
| US6148232A (en) * | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US7171264B1 (en) * | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US6300108B1 (en) * | 1999-07-21 | 2001-10-09 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
| US6928318B2 (en) * | 2000-05-22 | 2005-08-09 | Merck & Co., Inc. | System and method for assessing the performance of a pharmaceutical agent delivery system |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US20080269153A1 (en) * | 2002-05-28 | 2008-10-30 | Ruxandra Draghia-Akli | Increased stability of a dna formulation by including poly-l-glutamate |
| US7328064B2 (en) * | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| DK1628749T3 (da) | 2003-05-30 | 2019-09-16 | Vgxi Inc | Anordninger og fremgangsmåder til biomateriel produktion |
-
2007
- 2007-10-17 KR KR1020097007847A patent/KR101421760B1/ko active Active
- 2007-10-17 EP EP07839621.5A patent/EP2066399B1/en active Active
- 2007-10-17 EP EP24191208.8A patent/EP4477254A3/en active Pending
- 2007-10-17 DK DK07839621.5T patent/DK2066399T3/en active
- 2007-10-17 ES ES18198349T patent/ES2993941T3/es active Active
- 2007-10-17 EP EP18198349.5A patent/EP3524316B1/en active Active
- 2007-10-17 AU AU2007313203A patent/AU2007313203B2/en active Active
- 2007-10-17 EP EP11184546.7A patent/EP2409727B1/en active Active
- 2007-10-17 LT LTEP18198349.5T patent/LT3524316T/lt unknown
- 2007-10-17 JP JP2009533358A patent/JP5439183B2/ja active Active
- 2007-10-17 CA CA2666501A patent/CA2666501C/en active Active
- 2007-10-17 WO PCT/US2007/022139 patent/WO2008048632A1/en not_active Ceased
- 2007-10-17 PT PT181983495T patent/PT3524316T/pt unknown
- 2007-10-17 PL PL18198349.5T patent/PL3524316T3/pl unknown
- 2007-10-17 HU HUE11184546A patent/HUE042044T2/hu unknown
- 2007-10-17 US US11/874,072 patent/US9452285B2/en active Active
- 2007-10-17 FI FIEP18198349.5T patent/FI3524316T3/fi active
- 2007-10-17 CN CN201510716613.XA patent/CN105457157B/zh active Active
- 2007-10-17 SG SG2011074937A patent/SG175627A1/en unknown
- 2007-10-17 PT PT07839621T patent/PT2066399T/pt unknown
- 2007-10-17 DK DK18198349.5T patent/DK3524316T3/da active
- 2007-10-17 HU HUE18198349A patent/HUE069139T2/hu unknown
- 2007-10-17 ES ES11184546T patent/ES2703744T3/es active Active
- 2007-10-17 PL PL11184546T patent/PL2409727T3/pl unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| CN1345610A (zh) * | 2000-09-30 | 2002-04-24 | 杭州泰士生物科技有限公司 | 一种活体组织电穿孔用的波形及波形发生器 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105457157B (zh) | 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 | |
| TWI246930B (en) | Electro-kinetic device and electrode disk for electroporation and method for electroporating cells | |
| US6972013B1 (en) | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation | |
| Luxembourg et al. | Electroporation-based DNA immunisation: translation to the clinic | |
| CN102905755B (zh) | 可耐受的微创性皮肤电穿孔装置 | |
| JP2003505114A (ja) | パルス電場による皮膚および筋肉を標的とした遺伝子治療 | |
| EP4157226B1 (en) | Devices and systems for facilitating tissue delivery of drug | |
| CN101563132A (zh) | 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法 | |
| US20100191174A1 (en) | Hand-held electrical stimulation device | |
| JP2012521265A (ja) | ポリヌクレオチドがんワクチンを哺乳動物の皮膚に送達する方法と装置 | |
| HK1131756A (en) | Electroporation devices and methods of using same for electroporation of cells in mammals | |
| HK1131756B (en) | Electroporation devices and methods of using same for electroporation of cells in mammals | |
| Hannaman et al. | Delivery Technology Reenergizes DNA Drug Development | |
| Ronchetti et al. | Electroporation-Based Gene Transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: American Pennsylvania Applicant after: INOVIO PHARMACEUTICALS, Inc. Address before: American Pennsylvania Applicant before: Inovio Biopharmaceutical Co. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190402 Address after: American Pennsylvania Applicant after: Inovio Biopharmaceutical Co. Address before: American California Applicant before: VGX Pharmaceutical Co.,Ltd. Effective date of registration: 20190402 Address after: American California Applicant after: VGX Pharmaceutical Co.,Ltd. Address before: American Pennsylvania Applicant before: VGX Pharmaceuticals, Inc. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160406 Assignee: ADVACCINE (SUZHOU) BIOPHARMACEUTICAL Co.,Ltd. Assignor: INOVIO PHARMACEUTICALS, Inc. Contract record no.: X2022990000035 Denomination of invention: Electroporation device and method for electroporation of mammalian cells with it Granted publication date: 20200414 License type: Exclusive License Record date: 20220117 |
|
| EE01 | Entry into force of recordation of patent licensing contract |